The targeted delivery of IL17 to the mouse tumor neo-vasculature enhances angiogenesis but does not reduce tumor growth rate.
about
IL-17+Foxp3+ T cells: an intermediate differentiation stage between Th17 cells and regulatory T cellsImmunocytokines and bispecific antibodies: two complementary strategies for the selective activation of immune cells at the tumor siteLatent cytokines for targeted therapy of inflammatory disorders.Tumor rim cells: From resistance to vascular targeting agents to complete tumor ablation.Evolution of the magic bullet: Single chain antibody fragments for the targeted delivery of immunomodulatory proteins.The antibody-based targeted delivery of interleukin-4 and 12 to the tumor neovasculature eradicates tumors in three mouse models of cancer.
P2860
The targeted delivery of IL17 to the mouse tumor neo-vasculature enhances angiogenesis but does not reduce tumor growth rate.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
The targeted delivery of IL17 ...... not reduce tumor growth rate.
@en
The targeted delivery of IL17 ...... not reduce tumor growth rate.
@nl
type
label
The targeted delivery of IL17 ...... not reduce tumor growth rate.
@en
The targeted delivery of IL17 ...... not reduce tumor growth rate.
@nl
prefLabel
The targeted delivery of IL17 ...... not reduce tumor growth rate.
@en
The targeted delivery of IL17 ...... not reduce tumor growth rate.
@nl
P2860
P1433
P1476
The targeted delivery of IL17 ...... not reduce tumor growth rate.
@en
P2093
Katharina Frey
Nadine Pasche
P2860
P2888
P304
P356
10.1007/S10456-011-9239-8
P50
P577
2011-11-04T00:00:00Z